Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days prior to screening; no major surgery, other than diagnostic surgery, is allowed within 4 weeks prior to treatment in the study
Major surgery or significant traumatic injury within 14 days prior to therapy
Major surgery or significant traumatic injury <28 days prior to the first RO6874281 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Participant has not fully recovered from major surgery or significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 6 months after the last dose of study drug
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients who have had a major surgery or significant traumatic injury within 2 weeks of start of study drug
Major surgery or significant traumatic injury <28 days prior to Cycle 1 Day 1 (excluding fine needle biopsies) or anticipation of the need for major surgery during study treatment
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery or significant traumatic injury within 60 days prior to enrollment
Patients who have had major surgery or significant traumatic injury within 4 weeks prior to registration, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study
Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment; endoscopic debridement of RRP lesions is NOT considered a major surgery
Major surgery or significant traumatic injury less than (<) 28 days prior to the first cergutuzumab amunaleukin infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
=< 28 days before first dose of protocol-indicated treatment:\r\n* Anti-cancer treatment with bevacizumab.\r\n* Major surgery requiring general anesthesia or significant traumatic injury.
Major surgery or significant traumatic injury greater than or equal to 28 days prior to the first LMB-100 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Patients must have fully recovered from the effects of any major surgery or significant traumatic injury within 14 days of course 1 day 1 (C1D1)
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before first treatment
Participants must have recovered from the effects of major surgery requiring general anesthesia or significant traumatic injury at least 14 days before treatment arm assignment
Major surgery or significant traumatic injury within 14 days prior to Cycle 1 Day 1
Patients, who have had a major surgery or significant traumatic injury (injury requiring > 4 weeks [28 days] to heal) within 4 weeks (28 days) of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that are expected to require major surgery, other than cytoreductive nephrectomy +/- retroperitoneal lymph node dissection, during the course of the study.
Subjects who have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.
Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before registration
Major surgery or significant traumatic injury occurring within 21 days prior to treatment
Patients, who have had a major surgery or significant traumatic injury (injury requiring > 4 weeks [28 days] to heal) within 4 weeks (28 days) of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that are expected to require major surgery during the course of the study
Major surgery or significant traumatic injury =< 28 days prior to the first LMB-100 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Major surgery or significant traumatic injury within 2 weeks of run-in
Major surgery or significant traumatic injury occurring within 21 days prior to treatment
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Failure to recover from major surgery or traumatic injury within 4 weeks or minor surgery within 2 weeks prior to Day 1 of treatment.
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Subjects must have recovered from the effects of major surgery requiring general anesthetic or significant traumatic injury at least 14 days before Study Day 0.
Major surgery within 28 days prior to the first study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
Surgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during study treatment
Major surgery or significant traumatic injury that is not recovered at least 14 days before the initiation of thoracic radiation therapy
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery or significant traumatic injury within 4 weeks of first study drug
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment.
Patients who have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drug
Major surgery or significant traumatic injury within 4 weeks prior to study entry.
undergone major surgery or suffered from significant traumatic injury
Major surgery, or significant traumatic injury occurring within 21 days prior to treatment
Major surgery or significant traumatic injury within 8 weeks of first study drug; a core pancreatic or liver biopsy does not preclude the patient from the study
Patients who:\r\n* Have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drug\r\n* Have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or\r\n* Are anticipated to require major surgery during the course of the study
Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
Fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment
Subjects who have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
Major surgery, or significant traumatic injury within 4 weeks prior to study entry
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Major surgery or significant traumatic injury within 4 weeks of first study drug
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug,
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study
Has had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment
Major surgery or traumatic injury within 28 days of randomization
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before enrollment
Major surgery or significant traumatic injury < 28 days prior to the first RO6927005 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Major surgery or significant traumatic injury within 14 days of Cycle 1 Day 1.
History of major surgery or traumatic injury =< 28 days prior to registration or other major anticipated procedures requiring general anesthesia during study participation
Significant traumatic injury or major surgery (major surgery means opening of a body cavity, eg, thoracotomy, laparotomy, laparoscopic organ resection, and major orthopedic procedures, eg, joint replacement, open reduction and internal fixation) within 21 days of scheduled dosing day 1;
Major surgery or significant traumatic injury within 4 weeks of first study treatment from which the subject has not fully recovered
Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Major surgery or significant traumatic injury within 4 weeks of randomization or patients that may require major surgery during the course of the study.
Patients who have had a major surgery of significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients who have not recovered from the side effects of a major surgery or significant traumatic injury or patients that may require major surgery during the course of the study
Full recovery from the effects of any major surgery or significant traumatic injury within 14 days prior to the first dose of study treatment
Major surgery or significant traumatic injury occurring within 4 weeks before randomization
Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
